The proposed biosimilar references Genentech’s Pulmozyme, a biologic first approved in the early 1990s in both the European Union and the United States. Pulmozyme is used in conjunction with other therapies to improve pulmonary function in patients with cystic fibrosis.
JHL Biotech has announced that the Dutch Healthcare Authority has approved a clinical trial application for the company’s proposed biosimilar of the cystic fibrosis drug dornase alfa. JHL will begin the phase 1 clinical trial of JHL1922 in the Netherlands beginning this month, March 2018.
The proposed biosimilar references Genentech’s Pulmozyme, a biologic first approved in the early 1990s in both the European Union and the United States. Pulmozyme is used in conjunction with other therapies to improve pulmonary function in patients with cystic fibrosis. A recombinant human deoxyribonuclease 1 enzyme that selectively treats cystic fibrosis based on genetic markers, dornase alfa has also been shown to reduce the risk of respiratory tract infections that require parenteral antibiotics. The biologic is administered daily using a rapid nebulizer system or a jet nebulizer connected to an air compressor.
If JHL1922 is eventually approved, a cheaper biosimilar could expand access to dornase alfa treatment for the approximately 100,000 patients with cystic fibrosis worldwide. According to JHL’s own estimates, the annual cost of Pulmozyme per patient ranges from $12,000 to $40,000.
However, just as a potential biosimilar nears for this drug that has become a mainstay in treating the symptoms of cystic fibrosis, newer therapies that target the underlying cause of the disease are reaching the market; drug maker Vertex announced in February that the FDA had approved its tezacaftor/ivacaftor and ivacaftor combination (Symdeko) in patients with at least 1 genetic mutation that is responsive to tezacaftor plus ivacaftor. The newly approved drug addresses the trafficking and processing defect of a gene that causes cystic fibrosis.
While the therapy offers a new treatment option for patients, it comes as a cost far higher than that of dornase alfa; Vertex’s drug carries a list price of $292,000 per patient per year. Vertex is also the sponsor of other high-cost cystic fibrosis therapies, including the $311,000-per-patient-per-year ivacaftor (Kalydeco), and multiple investigational drugs currently in phase 3 studies.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.